Filing Details

Accession Number:
0001213900-19-023778
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-11-15 18:53:04
Reporting Period:
2019-11-13
Accepted Time:
2019-11-15 18:53:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1484565 Soleno Therapeutics Inc SLNO () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1398936 Vivo Ventures V Affiliates Fund, L.p. C/O Vivo Capital Llc
192 Lytton Avenue
Palo Alto CA 94301
No No Yes No
1398937 Vivo Ventures Fund V, L.p. C/O Vivo Capital Llc
192 Lytton Avenue
Palo Alto CA 94301
No No Yes No
1399028 Vivo Ventures V, Llc C/O Vivo Capital Llc
192 Lytton Avenue
Palo Alto CA 94301
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-11-13 14,229 $1.55 3,871,997 No 4 S Indirect See Footnote
Common Stock Disposition 2019-11-14 31,391 $1.55 3,840,606 No 4 S Indirect See Footnote
Common Stock Disposition 2019-11-15 51,404 $1.55 3,789,202 No 4 S Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
Footnotes
  1. The shares of common stock are held of record by Vivo Ventures Fund V, L.P. and Vivo Ventures V Affiliates Fund, L.P. ("Vivo Fund V"). Vivo Ventures V, LLC is the sole general partner of Vivo Fund V, and may be deemed to beneficially own the shares of common stock owned by Vivo Fund V. Vivo Ventures V, LLC disclaims beneficial ownership of the shares of Issuer held by Vivo Fund V, except to the extent of its pecuniary interest therein. The voting members of Vivo Ventures V, LLC are Frank Kung, Albert Cha and Edgar Engleman, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
  2. The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.55 to $1.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
  3. The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.55 to $1.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
  4. The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.55 to $1.555, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.